openPR Logo
Press release

Angina Pectoris Treatment Market Analysis And Growth Rate and top key players Abbott Laboratories, Astra Zeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche

07-09-2019 03:57 PM CET | Health & Medicine

Press release from: Coherent Market Insight

Angina Pectoris Treatment Market

Angina Pectoris Treatment Market

Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more of the heart’s arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to uncomfortable pressure, fullness, squeezing or pain in the center of the chest. The factors that trigger stable angina pectoris include, emotional stress, exposure to very hot or cold temperature, heavy meals or smoking. Angina pectoris can be diagnosed by an electrocardiogram and angiography and could be treated by medication, change in life style, and surgery. A minimal invasive procedure known as angioplasty is also used to treat the angina pectoris. The pain or discomfort caused by angina pectoris is relieved with rest and nitroglycerin. Nitroglycerin relaxes the coronary arteries and other blood vessels by increasing the blood flow to the heart vessels.

Get Sample Copy Of Report at @
https://www.coherentmarketinsights.com/insight/request-sample/1158

Angina Pectoris Treatment Market Taxonomy

By Drug Class:

Beta blockers
Calcium channel blockers
Nitrates
Angiotensin-converting enzyme inhibitors
Other

By Indication:
Stable Angina
Unstable Angina
New product launches and strong pipeline is expected to fuel the growth of angina pectoris treatment market

Espero announced in June 2016, that the company received approval from the U.S. Food and Drug Administration (FDA) for GoNitro (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris, due to coronary artery disease. In February 2016, AstraZeneca sold the rights of its two medicines Plendil and Imdur for US $500Mn. China Medical System Holdings (CMS) agreed to pay AstraZeneca US $310 million for commercialization rights of Plendil (felodipine) in China. Plendil is a calcium antagonist indicated for both hypertension and the prophylaxis of the chronic stable angina pectoris. Whereas, Imdur is an oral extended-release formulation of isosorbide mononitrate indicated for the prevention of angina pectoris, due to coronary artery disease.

Furthermore, Amgen offers a product named Corlanor (Ivabradine) for the treatment of angina pectoris in its pipeline (phase 3), which was presented by the company in year 2015 at Annual Scientific Session. In November 2016, Allergan also presented new data on BYSTOLIC (nebivolol) for the treatment of hypertension to lower blood pressure at the Annual American Heart Association Meeting in New Orleans. Whereas, Perrigo announced FDA approval of its abbreviated new drug application (ANDA) for Nitroglycerin Lingual Spray in 2013, the generic version of Shionogi's Nitrolingual Pumpspray indicated for acute attacks and prophylaxis of angina pectoris.

Strategic activities by market players to increase their market share

Angina pectoris treatment market is driven by factors, such as increasing number of collaborations, product launches, and mergers and acquisition. For instance, Recordati acquired AstraZeneca blood pressure brand Metoprolol, in 2017, which is a beta-blocker used mainly for the conditions, such as angina pectoris, hypertension, and heart disorders. Furthermore, Pharmaceutical manufacturer Lupin received approval from U.S. FDA in 2017 to launch the generic version of the U.S WorldMeds’ nadolol drug indicated for the patients with angina pectoris and for the treatment of hypertension. Moreover, patent expiry of Ranolazine drug from Gilead Sciences, Inc. in 2019 would mark the opportunity for generic drug manufacturers in the global angina pectoris treatment market.

Get PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1158

The key players operating in the global market of angina pectoris treatment market include Abbott Laboratories, Astra Zeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Allergan plc, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and Sanofi SA.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Angina Pectoris Treatment Market Analysis And Growth Rate and top key players Abbott Laboratories, Astra Zeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche here

News-ID: 1800224 • Views:

More Releases from Coherent Market Insight

Cervical Dysplasia Market Size Likely to be valued at US$ 784.8 Million by 2030, Future Trends, Key Insights and Business Strategies for F. Hoffmann La-Roche Ltd., QIAGEN N.V., Becton, Dickinson and Company
Cervical Dysplasia Market Size Likely to be valued at US$ 784.8 Million by 2030, …
Cervical dysplasia, a condition characterized by abnormal cell changes in the cervix, is often linked to human papillomavirus (HPV) infection and smoking. It primarily affects women above the age of 30. However, it's crucial to note that cervical dysplasia is preventable, and regular cervical screening tests play a vital role in the early diagnosis of precancerous stages. This overview focuses on the key factors associated with cervical dysplasia and highlights preventive
High Potency Active Pharmaceutical Ingredients Market Size Likely to be valued at US$ 40.99 Billion by 2030, Booming Growth, Outlook, and Future Prospects | Biomedica Management Corporation, NuvOxPharma LLC
High Potency Active Pharmaceutical Ingredients Market Size Likely to be valued a …
The global High Potency Active Pharmaceutical Ingredients market size is expected to reach USD 40.99 billion by 2030, registering a CAGR of 9.9% from 2023 to 2030, according to a new report by Coherent Market Insight Inc. High potency active pharmaceutical ingredients (HPAPIs) encompass small-molecule compounds, biologics, and antibody-drug conjugates that play a crucial role in modern medicine. With their ability to precisely and selectively target diseased cells, HPAPIs have
Virtual Rehabilitation and Telerehabilitation System Market is a rapidly growing industry Overview 2030 by Top Key Players | Reflexion Health, 270 Vision Ltd., CoRehab srl
Virtual Rehabilitation and Telerehabilitation System Market is a rapidly growing …
The global virtual rehabilitation and telerehabilitation systems market is expected to exhibit a CAGR of 19.2% during the forecast period (2023-2030). Manufacturers are focused on development and launch of innovative rehabilitation devices, which is expected to drive the virtual rehabilitation and telerehabilitation systems market growth. For instance, in August 2019, Ekso Bionics Holdings launched its EksoNR, the next generation of its EksoGT robotic exoskeleton, developed for neurorehabilitation purposes. The device is
Single Cell Analysis Market 2023-2030 | Industry Insights | Future Trends | Booming Growth | 10X Genomics, Abcam, Agilent
Single Cell Analysis Market 2023-2030 | Industry Insights | Future Trends | Boom …
Single cell analysis allows for the study of individual cells within a complex biological system, providing a more detailed and comprehensive understanding of cellular behavior and function. This technology has been instrumental in advancing research in various fields, including cancer biology, immunology, and neuroscience. One of the key drivers of the single cell analysis market is the increasing demand for personalized medicine. As researchers gain a better understanding of individual cell

All 5 Releases


More Releases for Angina

Angina Pectoris Drugs Market Set for Rapid Growth
Global Angina Pectoris Drugs Market: Overview The demand within the global market for angina pectoris drugs has been rising on account of the focus given on treating medical conditions suffered by the geriatric population. The presence of a seamless industry for healthcare diagnostic and treatment has played a major role in market growth. Angina pectoris is a type of chest pain that is triggered due to reduced blood flow to
Refractory Angina Market accentuating the growth 2025
Global Refractory Angina Market: Snapshot In simple terms, refractory angina (RFA) is a disabling chronic heart pain, as a result of heart disease. Angioplasty, coronary artery bypass surgery, or even medical therapy have failed to control this chest pain. A chronic chest pain can be determined if it occurs longer than three months. The blockage of arteries takes place due to a build-up of plaque. As a result, blood flow slows
Angina (Angina Pectoris) Key Players - Angionetics Inc, Hemostemix Inc, and ID P …
Angina (Angina Pectoris) Overview Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high
Angina Pectoris Treatment Market - Global Industry Insights, 2025
Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more of the heart’s arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to uncomfortable pressure, fullness, squeezing or pain in the center of the chest.
Angina (Angina Pectoris) Pipeline Review, H2 2017
The Report Angina (Angina Pectoris) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina (Angina Pectoris) - Pipeline Review, H2 2017, provides an overview of the Angina (Angina Pectoris) (Cardiovascular) pipeline landscape. Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs
Refractory Angina Market: Industry Survey and Outlook 2025
Global Refractory Angina Market: Snapshot In simple terms, refractory angina (RFA) is a disabling chronic heart pain, as a result of heart disease. Angioplasty, coronary artery bypass surgery, or even medical therapy have failed to control this chest pain. A chronic chest pain can be determined if it occurs longer than three months. The blockage of arteries takes place due to a build-up of plaque. As a result, blood flow slows